VCCT Inc. was established in March2021 as a wholly owned subsidiary of Vision Care Inc. (certified as a RIKEN Venture).
The Company conducts research and development in the fields of ophthalmology and regenerative medicine for the purpose of research and development of technologies related to regenerative medicine, etc., manufacture and sale of goods, acquisition, possession, licensing, transfer and management of intellectual property, and early practical application of regenerative medicine.
|Company Name||VCCT Inc.|
|Representative||Masayo Takahashi , President and Representative Director|
|Location||Kobe Eye Center 5F, 2-1-8 Minatojima-minamimachi, Chuo-ku, Kobe 650-0047, Japan|
|Founded||March 8, 2021|
|Fiscal Year End||End of February|
|Business||・Research and development of technologies related to regenerative medicine
・Manufacture, sale and import/export of goods related to regenerative medicine
・Acquisition, possession, licensing, transfer and management of intellectual property such as industrial property rights and copyrights
|Parent company||Vision Care Inc.|
|Group Company||VCGT Inc.|
President and CEO
Masayo Takahashi MD, PhD
- Councilor, Japan Ophthalmological Society
- Executive Director, Japan Society for Regenerative Medicine
- Executive Director, Japan Retina and Vitreous Society
- Vice Chairman, Japan Retinitis Pigmentosa Society
- Director, Public Interest Incorporated Foundation NEXT VISION
- Fellow, Ritsumeikan Advanced Research Academy (RARA), Ritsumeikan University
- Senior Adviser, Research Center, Kobe City Eye Hospital Membership in International Organizations
- The Association for Research in Vision and Ophthalmology (ARVO)
- Academia Ophthalmologica Internationalis (AOI)
- International Member, National Academy of Medicine (NAM)
- Associate Member, European Molecular Biology Organization (EMBO)
Masayo Takahashi is an ophthalmologist who completed her doctoral program (Visual Pathology) at the Graduate School of Medicine, Kyoto University. She served as the leader of the Laboratory for Retinal Regeneration, RIKEN Center for Biosystems Dynamics Research from 2006 to 2022, conducting groundbreaking clinical research using the world’s first induced pluripotent stem (iPS) cells in 2014.
In 2017, she collaborated with the city of Kobe to establish the “Kobe Eye Center.” After leaving RIKEN in 2019, she became the CEO of Vision Care Inc. and subsequently founded two subsidiary companies dedicated to gene therapy development and cell therapy research.
Director and CTO
Seiji Hori PhD
Seiji Hori graduated from the Graduate School of Science at Kyoto University. He worked as a researcher at Maruha Corp., Novartis, and Osaka Bioscience Institute, and then became a lecturer in graduate school of biostudies of Kyoto University. Since 2014, he has been involved in regenerative medicine and drug discovery business consulting at iPS Portal,Inc. He also holds the position of Team Leader for Cell and Gene Therapy in Ophthalmology Laboratory, RIKEN Baton Zone Program, advancing research and development in Regenerative Medicine within the Vision Care Group. Additionally, he serves as a visiting professor at Hiroshima University and an adjunct lecturer (Biomedical Engineering and Regenerative medical science) at Kyoto Sangyo University.
Director and COO
Tomoki Otani PhD
Tomoki Otani graduated from the University of Cambridge. He worked as a researcher at the University of Cambridge’s Gurdon Institute and later served as an Associate Partner at McKinsey & Company. With a broad perspective, he leads research and development and business strategy efforts, working on strategic planning for domestic and international pharmaceutical companies within the Vision Care Group, as well as contributing to corporate transformation.
Director and CFO
After graduating from the Faculty of Education at Waseda University, Takuma Fukuda worked at Daiwa Securities Co. Ltd. before founding BuzzBox Inc. engaged in recruitment support services, which he later sold. He has since focused on investment and business development in the healthcare and human resources sectors. Leveraging his diverse experiences, he is actively involved in the management of the Vision Care Group as a founding member.
Takaaki Oe is a certified public tax accountant who Established the Oe Accounting Firm in 1998. In 2000, he established Kyoto Management Consulting Co., Ltd. and became its representative director, and in 2007, he established Kyoto Management Tax Corporation and became its representative partner.
Transportation and Access Information
2 minutes walk from “Iryo Center” station of Portliner.
Please take the train bound for Kobe Airport. Please note that the bus bound for “North Pier” does not stop at this station.
From Kobe Airport
Please take the Port Liner through the connecting passageway from the 2nd floor of the Airport Terminal Building.
Follow signs for Port Island from all directions. It takes about 15 minutes after crossing Kobe Ohashi.
You can also use Minatojima Tunnel in Sannomiya East.
Using Hanshin Expressway Route 3
Exit at “Ikuta River IC” or “Kyobashi IC” and follow the signs for Port Island.
Using Hanshin Expressway Wangan Route 5
Exit at “Sumiyoshigawa IC” and proceed via “Harbor Highway” and follow the signs for Port Island.
Parking is available at the Advanced Medical Center and Kobe Eye Center. Parking for general use is available 24 hours a day. Fee: 160 yen per hour (daily limit is 1,000 yen).
＊1-3 hours may be free depending on the nature of use.